Company Monitoring Page for Novartis

latest headlines for company on cafepharma

Upcoming events – Phase III data for Chiasma and Novartis
EP Vantage
Fri, 05/17/19 - 07:23 pm
Tags:
Chiasma, acromegaly, Mycapssa, clinical trials, multiple sclerosis, Novartis, ofatumumab
Commentary: Novartis CEO: Gene therapy offers hope of cures in one treatment, but US needs new pricing and payment model
CNBC
Fri, 05/17/19 - 07:21 pm
Tags:
gene therapy, cancer, Novartis, Pharma CEOs, Vas Narasimhan
Alcon Beats Expectations Since its Split from Novartis
Medical Devices and Diagnostics Industry
Fri, 05/17/19 - 07:13 pm
Tags:
Alcon, earnings, Novartis, eye health
Better than CAR-T? Already prepping for a US launch, MorphoSys posts stellar DLBCL data to field against Novartis, Gilead
Endpoints
Fri, 05/17/19 - 01:03 pm
Tags:
CAR-T, MorphoSys, Novartis, Gilead Sciences, tafasitamab, DLBCL
Novartis takes another step forward in global Kymriah rollout as Japan OKs the drug at $305K
Endpoints
Wed, 05/15/19 - 10:31 am
Tags:
Novartis, Kymriah, Japan, CAR-T
Novartis' Sandoz does digital from back office to 'not just apps' therapeutics
Fierce Pharma
Tue, 05/14/19 - 05:04 pm
Tags:
digital pharma, Sandoz, Novartis
Novartis’ Gilenya proves superiority over glatiramer acetate in relapsing remitting MS
Pharmaceutical Business Review
Mon, 05/13/19 - 08:14 pm
Tags:
Novartis, Gilenya, Relapsing Remitting Multiple Sclerosis
Novartis vows to fight U.S. price-fixing claims against Sandoz unit
Yahoo/Reuters
Mon, 05/13/19 - 09:24 am
Tags:
Novartis, Sandoz, generics, price fixing
Takeda sells Shire’s Xiidra, transfers 400 staffers to Novartis in $3.4B deal
Fierce Pharma
Thu, 05/9/19 - 11:11 am
Tags:
Takeda, Shire, Novartis, M&A, Xiidra, dry eye disease
Novartis sees Saudi Arabia as promising market for producing its cancer drugs
Fierce Pharma
Thu, 05/9/19 - 11:04 am
Tags:
Novartis, oncology, cancer, Saudi Arabia
Pushing hard for blockbuster returns, Novartis finds PhIII data to assert Mayzent boosts cognitive powers in MS patients
Endpoints
Thu, 05/9/19 - 10:43 am
Tags:
Novartis, Mayzent, siponimod, multiple sclerosis
Novartis Considers Offer for Takeda Eye-Disease Assets
Bloomberg
Wed, 05/8/19 - 05:25 pm
Tags:
Novartis, Takeda, Shire, eye disease, M&A
Roche, PTC post latest SMA data from their attempt to rival Spinraza, Zolgensma
Fierce Biotech
Tue, 05/7/19 - 10:19 am
Tags:
Roche, PTC Therapeutics, spinal muscular atrophy, risdiplam, Novartis, Zolgensma, Biogen, Spinraza
New Zolgensma data suggest comparable efficacy to Spinraza — analysts
Endpoints
Mon, 05/6/19 - 09:52 pm
Tags:
Novartis, FDA, spinal muscular atrophy, Zolgensma, AveXis, Biogen, Spinraza
FDA Raises Concerns With Novartis in Clinical Inspection
RAPS.org
Mon, 05/6/19 - 07:30 pm
Tags:
Novartis, FDA, Mayzent, siponimod, clinical trials, multiple sclerosis
Novartis makes final Zolgensma pitch before FDA decision
BioPharma Dive
Sun, 05/5/19 - 06:51 pm
Tags:
Novartis, gene therapy, Zolgensma, FDA, spinal muscular atrophy
SMA Moment: Will Gene Therapy Shift Treatment, Costs of Muscle Disease?
Xconomy
Thu, 05/2/19 - 11:00 am
Tags:
gene therapy, SMA, spinal muscular atrophy, Novartis, Zolgensma
Can 'synthetic lethality' and deep experience propel this cancer-fighting biotech's $70M IPO?
Bizjournals
Tue, 04/30/19 - 09:37 am
Tags:
Ideaya, Novartis, IPOs, cancer
How a Medicare Rule Change Could Bring CAR-T Stocks Back to Life
Motley Fool
Sat, 04/27/19 - 10:47 am
Tags:
Gilead Sciences, Novartis, CMS, Medicare, CAR-T
Pharma Giant Novartis Eyes Better 2019 Profit And 3 New Blockbuster Hopefuls
Investors Business Daily
Wed, 04/24/19 - 12:10 pm
Tags:
Novartis, earnings

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.